Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $17.10.
A number of research analysts have recently commented on the company. Truist Financial reiterated a “buy” rating and issued a $23.00 price objective on shares of Roivant Sciences in a report on Monday, March 25th. Piper Sandler upped their target price on Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft increased their price objective on Roivant Sciences from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. The Goldman Sachs Group increased their target price on Roivant Sciences from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research note on Tuesday, June 18th.
Check Out Our Latest Research Report on ROIV
Roivant Sciences Trading Up 1.0 %
Roivant Sciences (NASDAQ:ROIV – Get Free Report) last released its quarterly earnings data on Thursday, May 30th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. Roivant Sciences had a negative return on equity of 25.05% and a net margin of 3,484.86%. The business had revenue of $28.93 million for the quarter, compared to the consensus estimate of $32.46 million. As a group, equities research analysts expect that Roivant Sciences will post -1.12 EPS for the current fiscal year.
Institutional Investors Weigh In On Roivant Sciences
Institutional investors have recently added to or reduced their stakes in the company. Nordea Investment Management AB acquired a new stake in Roivant Sciences in the first quarter worth approximately $2,851,000. Citigroup Inc. increased its holdings in shares of Roivant Sciences by 45.6% in the third quarter. Citigroup Inc. now owns 326,431 shares of the company’s stock valued at $3,813,000 after buying an additional 102,279 shares in the last quarter. Mutual of America Capital Management LLC increased its holdings in shares of Roivant Sciences by 116.8% in the first quarter. Mutual of America Capital Management LLC now owns 325,937 shares of the company’s stock valued at $3,435,000 after buying an additional 175,574 shares in the last quarter. State of Michigan Retirement System bought a new position in shares of Roivant Sciences in the first quarter valued at $853,000. Finally, Retirement Systems of Alabama bought a new position in shares of Roivant Sciences in the first quarter valued at $4,464,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Stories
- Five stocks we like better than Roivant Sciences
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Top 3 Defense Stocks That Should Be on Your Radar
- Consumer Staples Stocks, Explained
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- MarketBeat Week in Review – 7/8 – 7/12
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.